{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:40:10Z","timestamp":1761896410306},"reference-count":48,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Histologic transformation (HT) is a frequent event in the clinical course of patients with indolent lymphoma. Most of the available data in the literature comes from studies on transformation of follicular lymphoma (FL), as this is the most common indolent lymphoma; however, HT is also well documented following small lymphocytic lymphoma\/chronic lymphocytic leukaemia (SLL\/CLL), lymphoplasmacytic lymphoma (LPL), or marginal zone lymphoma (MZL), amongst other types of lymphoma, albeit most of the studies on transformation in these subtypes are case reports or short series. The outcome of patients with HT has traditionally been considered dismal with a median overall survival (OS) of around 1 year in most of the published studies. This prompted many authors to include stem cell transplant (SCT) as part of the treatment strategy for young and fit patients with HT. However, recent articles suggest that the outcome of patients with transformed lymphoma might be improving, questioning the need for such intensive therapies. The management of patients with HT is challenged by the heterogeneity of the population in terms of previous number and type of therapy lines and from their exclusion from prospective clinical trials. This review will examine whether the advent of new therapies has impacted on the prognosis of HT and on current treatment strategies.<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.625","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T15:23:25Z","timestamp":1473953005000},"page":"625-630","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Treatment of patients with transformed lymphoma"],"prefix":"10.1182","volume":"2015","author":[{"given":"Silvia","family":"Montoto","sequence":"first","affiliation":[{"name":"Department of Haemato-oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"10","key":"2019111706224252700_B1","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdl162","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma","volume":"17","author":"Gine","year":"2006","journal-title":"Ann Oncol"},{"issue":"32","key":"2019111706224252700_B2","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111706224252700_B3","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients","volume":"15","author":"Bastion","year":"1997","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111706224252700_B4","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111706224252700_B5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1182\/blood.V94.2.448","article-title":"Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases","volume":"94","author":"Mauro","year":"1999","journal-title":"Blood"},{"issue":"15","key":"2019111706224252700_B6","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111706224252700_B7","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/cncr.22121","article-title":"Hodgkin transformation of chronic lymphocytic leukemia: the MD Anderson Cancer Center experience","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"2019111706224252700_B8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","article-title":"Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"142","author":"Rossi","year":"2008","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111706224252700_B9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1309\/R01VXG46MFCDVNHL","article-title":"Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma\/Waldenstrom macroglobulinemia: clinicopathologic features of 12 cases","volume":"120","author":"Lin","year":"2003","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"2019111706224252700_B10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/jcp.53.3.187","article-title":"Clinicopathological features of gastric mucosa associated lymphoid tissue (MALT) lymphomas: high grade transformation and comparison with diffuse large B cell lymphomas without MALT lymphoma features","volume":"53","author":"Yoshino","year":"2000","journal-title":"J Clin Pathol"},{"issue":"4","key":"2019111706224252700_B11","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/bjh.13320","article-title":"Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia","volume":"169","author":"Xing","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111706224252700_B12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.24819","article-title":"Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group","volume":"116","author":"Biasoli","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"2019111706224252700_B13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2009.24.9516","article-title":"Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma","volume":"28","author":"Al-Mansour","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111706224252700_B14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","article-title":"Incidence, risk factors and outcome of histological transformation in follicular lymphoma","volume":"157","author":"Conconi","year":"2012","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111706224252700_B15","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1200\/JCO.1995.13.7.1726","article-title":"Long-term survival after histologic transformation of low-grade follicular lymphoma","volume":"13","author":"Yuen","year":"1995","journal-title":"J Clin Oncol"},{"issue":"9383","key":"2019111706224252700_B16","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"2019111706224252700_B17","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111706224252700_B18","first-page":"11","article-title":"The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment","volume":"25","author":"Young","year":"1988","journal-title":"Semin Hematol"},{"issue":"4","key":"2019111706224252700_B19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111706224252700_B20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hon.2900080105","article-title":"Treatment of low-grade non-Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial","volume":"8","author":"Lepage","year":"1990","journal-title":"Hematol Oncol"},{"issue":"9583","key":"2019111706224252700_B21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"issue":"16","key":"2019111706224252700_B22","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","article-title":"First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia","volume":"114","author":"Eichhorst","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111706224252700_B23","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1023\/A:1008349427337","article-title":"High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre","volume":"9","author":"Foran","year":"1998","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111706224252700_B24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1034\/j.1600-0609.2000.90114.x","article-title":"Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma","volume":"65","author":"Berglund","year":"2000","journal-title":"Eur J Haematol"},{"issue":"1","key":"2019111706224252700_B25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1365-2141.2001.02705.x","article-title":"Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma","volume":"113","author":"Chen","year":"2001","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111706224252700_B26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2001.19.3.727","article-title":"High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry","volume":"19","author":"Williams","year":"2001","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111706224252700_B27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12570","article-title":"Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database","volume":"163","author":"Ban-Hoefen","year":"2013","journal-title":"Br J Haematol"},{"issue":"26","key":"2019111706224252700_B28","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111706224252700_B29","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00277-013-1991-y","article-title":"Survival of patients with transformed lymphoma in the rituximab era","volume":"93","author":"Guirguis","year":"2014","journal-title":"Ann Hematol"},{"issue":"6","key":"2019111706224252700_B30","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00277-015-2303-5","article-title":"Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis","volume":"94","author":"Lerch","year":"2015","journal-title":"Ann Hematol"},{"issue":"2","key":"2019111706224252700_B31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2006.06439.x","article-title":"Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms","volume":"136","author":"Davies","year":"2007","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111706224252700_B32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/annonc\/mdu537","article-title":"Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation","volume":"26","author":"Madsen","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"2019111706224252700_B33","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.bbmt.2007.04.009","article-title":"A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma","volume":"13","author":"Sabloff","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2019111706224252700_B34","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2141.2010.08519.x","article-title":"High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas: a Norwegian multi centre phase II study","volume":"152","author":"Eide","year":"2011","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111706224252700_B35","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/bjh.12176","article-title":"Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era","volume":"160","author":"Armand","year":"2013","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111706224252700_B36","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.2012.44.0693","article-title":"Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group","volume":"31","author":"Villa","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111706224252700_B37","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.bbmt.2014.03.014","article-title":"Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma","volume":"20","author":"Wirk","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2019111706224252700_B38","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/bmt.2008.220","article-title":"Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results","volume":"42","author":"Ramadan","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"2019111706224252700_B39","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","article-title":"Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation","volume":"30","author":"Cwynarski","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111706224252700_B40","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.bbmt.2014.07.015","article-title":"Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma","volume":"20","author":"Villa","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"2019111706224252700_B41","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111706224252700_B42","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdp237","article-title":"Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma","volume":"20","author":"Haioun","year":"2009","journal-title":"Ann Oncol"},{"issue":"36","key":"2019111706224252700_B43","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111706224252700_B44","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/jco.2010.28.15_suppl.8005","article-title":"Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy","volume":"28","author":"Pettengell","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111706224252700_B45","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2011.08781.x","article-title":"The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin","volume":"154","author":"Czuczman","year":"2011","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111706224252700_B46","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood"},{"issue":"33","key":"2019111706224252700_B47","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial","volume":"31","author":"Armand","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111706224252700_B48","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.clml.2012.07.003","article-title":"Superior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantation","volume":"12","author":"Reddy","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/625\/1249488\/bep00115000625.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/625\/1249488\/bep00115000625.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T11:23:03Z","timestamp":1573989783000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/625\/20545\/Treatment-of-patients-with-transformed-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.625","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}